Diabetes, particularly type 2 diabetes, is a chronic condition in which the body either produces insufficient insulin—a hormone that helps glucose enter cells—or becomes resistant to it. The disease affects nearly 600 million people globally. As of 2025, an estimated 589 million adults live with diabetes, accounting for roughly one in nine adults aged 20 to 79, according to the 11th edition of the IDF Diabetes Atlas.
Obesity is one of the most significant risk factors for type 2 diabetes, contributing to elevated blood sugar levels as excess glucose remains in the bloodstream instead of reaching cells for energy. Addressing obesity is therefore essential to managing diabetes, and a new Harvard study points to a potential breakthrough.
The research highlights the liver as a central hub that receives metabolites produced by gut microbes and distributes them throughout the body, influencing overall metabolism. These findings suggest future therapies could target gut-derived chemicals to regulate fat and glucose, offering a more holistic approach to managing obesity and diabetes.
Key Findings
The Harvard team, supported by FAPESP, studied mice with different genetic predispositions to obesity and diabetes. They identified over 110 gut-derived metabolites traveling from the intestine to the liver via the portal vein in metabolically healthy mice. In mice prone to obesity or diabetes and fed a high-fat diet, the diversity of these metabolites was significantly reduced.
Lab experiments showed that certain metabolites, such as mesaconate, improved insulin signaling and regulated fat storage and fat-burning processes in liver cells. This demonstrates a direct mechanism by which the gut microbiome influences how the body handles glucose and fat.
Building on Previous Research
Previous Harvard studies linked specific gut bacteria to type 2 diabetes risk, but primarily showed correlations between microbial composition and disease. The new study goes further by identifying specific metabolites and tracking their journey from the gut to the liver and bloodstream, strengthening the case for microbiome-targeted therapies alongside conventional treatments.
Implications for Treatment
Traditional diabetes and obesity management focuses on lifestyle changes, medications, weight-loss drugs, and sometimes surgery. This study suggests a complementary strategy: targeting gut-derived metabolic signals to reprogram energy and fat processing at a molecular level.
If researchers can identify microbial metabolites that protect against insulin resistance or promote healthy liver metabolism, they could develop drugs or dietary interventions that mimic these effects. This approach could transform diabetes and obesity treatment by addressing the root metabolic mechanisms rather than just symptoms.
Related topic：
